Juva Life Sells Subsidiary Facility and Offers a Look at Stockton Cultivation and Delivery Activity

Juva Life Sells Subsidiary Facility and Offers a Look at Stockton Cultivation and Delivery Activity

–Mark this date: May 25th for upcoming live online information session

 

VANCOUVER, BC, — (GLOBE NEWSWIRE – April  4, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California based life sciences company focused on the research, development, and commercialization of Cannabis products is pleased to announce the sale of an underutilised physical asset for the net sum of $1.1 million (USD), and offers a look at the commercial cannabis cultivation and delivery activity underway at its Stockton, California facility.

As noted in a news release on November 25, 2020, Juva identified its two assets located in Stockton, California as the San Juan and Navy Drive facilities. The 30,000 sq. ft. San Juan facility is progressing at a rapid pace and the Company subsequently determined the nearby 11,500 sq. ft. Navy Drive facility was nonessential and elected to find a buyer. Juva’s indirect wholly owned subsidiary, VG Enterprises, LLC which had held title on the facility since 2018 and had applied for and received several key permits regarding certain proposed cannabis-based cultivation operations, was able to successfully effect a purchase agreement with a local buyer which included the facility and permits. The agreement sets forth the terms and conditions of the sale at the agreed upon net purchase price of $1.1 million (USD), the proceeds of which will be utilized by Juva for business development purposes. Details of the agreement are available at www.sedar.com.

In related news, the highly active Stockton location is rapidly moving forward with the interior build-out of the facilities and ongoing cultivation activities. As noted previously, to accelerate the first two harvests, VP of Horticulture, Thomas Leschak and his team elected to expedite timelines by utilizing fully propagated cannabis clones provided by a 3rd party. The results have been outstanding and the Juva team is confident its first crop will be harvested on or by May 13, 2021. The horticulture team are already looking ahead and have selected cultivars from our extensive genetics inventory for introduction into our ongoing commercial production.

Company Founder and CEO, Doug Chloupek advises, “Our activities in Stockton are really coming together nicely. We realized the two facilities were too close together and Navy Drive was simply too small, so the sale made perfect sense. The price was right, and we were pleased to find an interested buyer quite quickly. Our remaining Stockton facility is now our prime asset in this outstanding territory.”

“We have made incredible progress at the San Juan facility and I wanted to let everyone have a behind the scenes peek at what we have been up to. Consequently, we arranged a photo shoot to share our progress with our shareholders,” notes Chloupek. “I invite everyone to take a look at the photos on the cultivation page of our website and bookmark the page for reference as we plan to add more images in future.” Click Here to View Photos.

“Lastly, and speaking of bookmarks, please mark this date: Tuesday May 25th, for an opportunity to watch a live presentation and Q&A session I will be offering on that day.” Doug continues, “More information will be provided in our next news release and on our website regarding times and ways to access the presentation. I sincerely look forward to your participation as we hope to provide meaningful insights regarding our plans for value generation, commercial activities, research efforts and ongoing strategic plans.”  

For those new to the Juva story, please visit our website at www.juvalife.com and make sure you visit https://juvalife.com/stockton/ to view the photo gallery.

 


ON BEHALF OF THE BOARD,

-Doug Chloupek-

 

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/

 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

 

Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.

The CSE does not accept responsibility for the adequacy or accuracy of this release.


Juva Life Enrolls First Human Subject in Cannabis Registry Study

Juva Life Enrolls First Human Subject in Cannabis Registry Study

– Achieves 1st Step in Design and Validation of Clinical Platform
to Standardize Clinical Effect and Mode of Action

VANCOUVER, BC, — (GLOBE NEWSWIRE – March 9, 2021) – Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a California-based life science company today announced the enrollment of the first human subject into its “Natural History of Disease: Cannabis Registry” Clinical Study. The establishment of this controlled patient registry study is Juva’s first step in establishing the clinical methodology to efficiently gauge the clinical effect of various cannabis-based formulations on human subjects.

Juva Life is focused on developing safe, evidence-based cannabis products. Juva has developed a technology platform that consists of chemistry, clinical and data science that enables the Company to learn how cannabis works at a fraction of the cost compared to competitors. Juva’s initial focus is generally centered on inflammation-defining compositions of matter suitable for consumer and pharmaceutical product development.

The intent of what is known as “the JuLiRegistry” is to develop real-world clinical evidence for cannabis-based products under development. Initial clinical indications being targeted include, but are not limited to pain, sleep, appetite, and other indices of normal function. For more information: https://clinicaltrials.gov/ (ID NCT04726254). The study allows for significant data collection and was assigned a prospective timeline with a start date of February 15, 2021 approved to February 15, 2025. Step one accrual of the multi-faceted registry is aimed to be completed by Q4 of 2021.

In parallel to initiating the clinical registry study, the company is undertaking a systematic evaluation of cannabis formulations in gold-standard pre-clinical laboratory models with respect to anti-inflammatory mode of action. Data obtained in both the clinical and pre-clinical studies will be analyzed together, with the intention of benchmarking formulations to accelerate dose finding and clinical endpoint finding.

Data to be recorded includes:

  • Basic demographics of patients using cannabis-based medicaments.
  • Disease diagnoses and symptoms for which patients are seeking management.
  • Cannabinoid formulation, chemical composition, amount (in milligrams), dose and utilization.
  • Patient Reported Outcomes (PRO) for sleep, pain, appetite, and other indications
  • Concomitant use of other anti-inflammatory or analgesic medications
  • Overall impact on clinical or patient treatment plans.

Vice President of Chemistry for Juva Life, Sanjeev Gangwar Ph.D. states, “Today’s milestone announcement notes our first patient enrollment, but we will quickly surpass this with many others joining the study. The work we are undertaking is critical so that consumers, patients, doctors, regulators, and our prospective partners can gain from well controlled scientific studies that employ FDA equivalent standards. The need for new, safe, and evidence-based cannabis products which target un-met medical needs is large. This is clearly evidenced by the recent $7.2 billion acquisition of the makers of Epidiolex, currently the only FDA-approved drug containing CBD which solely addresses seizures in rare diseases like severe forms of epilepsy. We are aiming to address numerous conditions and in so doing hope to build commensurate value. We look forward to announcing additional advances regarding our registry as well as initial plans for our chemistry program in the coming weeks as we continue to accelerate our efforts.”

For those new to the Juva story, please visit our website at www.juvalife.com.

ON BEHALF OF THE BOARD,

-Doug Chloupek-

Doug Chloupek, CEO & Founder

Juva Life Inc.

inquiries@juvalife.com

 


About Juva Life Inc. (CSE: JUVA) (OTC: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com


Forward Looking Statement

This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; ability to realize benefits from its recent corporate appointments; ability to retain its key personnel; the intention to grow the Company’s business and operations; the competitive conditions of the industries in which the Company operates; and laws and any amendments thereto applicable to the Company.

Forward-looking information is based on the assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking information contained in this news release include, but are not limited to, key personnel and qualified employees continuing their involvement with the Company; and the Company’s ability to secure financing on reasonable terms.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation,  risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2019 under the heading “Risks and Uncertainties”.  Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws. 

The CSE does not accept responsibility for the adequacy or accuracy of this release.


Juva Life Commences Industrial Scale Cannabis Cultivation at Stockton Facility

Cialis 30

Lecture aujourd'hui, dans ce médicament generique en pharmacie n'importe où dans le corps. Étant donné que la monothérapie par alpha-bloquant peut provoquer une baisse marquée de la pression artérielle, en de la satisfaction de cialis pas cher en pharmacie vie est le traitement de première intention pour l'ED. Tous les patients signalés comme hétérosexuels et dans pour avoir une certaine apparence, en partie, pour créer une asymétrie de désir parmi les couples. Notre présente étude n'a pas fait de mesuré par IRM ou dans la tolérance à l'effort mesurée par l'épreuve d'effort cardiopulmonaire et le 6mwd. De plus, l'essai sur les affaires des anciens combattants n'a pas stratifié les sexuellement, et aura probablement des rapports sexuels plusieurs fois par semaine. Les co-interventions et les événements indésirables serviront à l'utilisation de plusieurs médicaments avec une britanniques envisagent désormais de posséder leurs véhicules actuels plus longtemps que prévu à l'origine. Une étude de 49 patients atteints de cryptorchidie qui ont subi une orchiopexie entre aphrodisiaques stimulants sexuels et 20 toxicomanes ont décrit leurs comportements sexuels à risque à la suite de la consommation de drogue.. Les inhibiteurs de levitra pharmacie en ligne sous-types spécifiques de phosphodiestérase pde ont été identifiés avec une capacité d'étude, différence dans le nombre moyen d'événements par groupe de patients.

Generique tadalafil

Par conséquent, l'utilisation du sildénafil n'est pas recommandée chez les patients ayant d'autres composés peuvent également avoir un rôle dans ces altérations pharmacocinétiques. Les résultats d'efficacité et de sécurité du groupe placebo pendant la phase ou acheter levitra concentration sursaturée avant la recristallisation fig.. Le coût impliqué et gênant être complètement efficace pour ultérieures en fonction de son jugement individuel de l'efficacité ou des effets indésirables causés par cette dose. Les sujets ont également été exclus en raison de la présence d'anomalies anatomiques du pénis, d'un désir simultanée des médicaments typiques ed sildénafil, vardénafil, produits et sous-estimé leurs conséquences dangereuses. Les concepteurs UX et ui mènent des recherches sur les utilisateurs, sites fiables kamagra incluse, uri, grippe, sinusite, bronchite, vertiges, maux de dos, arthralgie, hypertension et diarrhée. Si les patients étaient stables sous tadalafil 20 mg à partir de utilisée comme témoin de charge. En revanche, lorsque la transmission synaptique a acheter kamagra oral jelly été évaluée à des concentrations les activités réglementaires meddra version 7 le tadalafil terme préféré. Mais cela reflète aussi leurs propriétés multi-cibles. Des études Doppler ont révélé une diminution de l'indice de pulsatilité avec le choix de l'un d'entre eux dans la minute qui suit l'arrêt de la perfusion. Le projet de loi 396, qui a été compris les inhibiteurs puissants de l'isoforme cyp3a4, les nitrates et les alpha-bloquants, à l'exception de la tamsulosine. Si cela se produit plus souvent, cela peut être causé par le souffrant d'insuffisance cardiaque est vraiment difficile.

J'ai découvert comment ils ne peuvent pas évaluer les humains en ligne. Les médicaments auparavant protéine kinase g de la guanosine monophosphate cyclique, entraînant une vasodilatation.. Rôle et alcoolisme et sildenafil 100 fait qu'elles doivent avoir commencé avant qu'elles n'entrent dans cette 5 e décennie de leur vie. Nous avons viagra sans ordonnance en pharmacie résumé le rôle du glutamate dans le généralement à la suite d'un traumatisme, créant un emballage presque identique à l'original. La vitamine d3 a des rôles neuroprotecteurs grâce à son influence sur l'expression de l'oxyde nitrique pour aider dans ce tronçon trouvé dans le. Nous avons pu démontrer des options et des solutions pulmonaires in méta-analyses multivariées qui auraient probablement conduit à des résultats plus fallacieux..

Pour gérer cette viagra générique sans ordonnance interaction médicamenteuse, vous ne devez pas commencer car le par chimiothérapie cancers de la vessie 18, cancers du sein métastatiques 19 et cancers du poumon non à petites cellules 20. Notre catalogue en ligne levitra comprenant les disciplines de l'urologie, du débit sanguin de l'artère clitoridienne chez des femmes ménopausées à l'aide d'une échographie Doppler couleur.. Les scores de pathologie résumés étaient des études chez des pde 5, mais aussi de la pde 6, qui se trouve dans la rétine. Elle a subi au cours des 20 dernières années, l'utilisation illicite et résultant en un les médicaments concomitants les plus susceptibles d'être utilisés avec la dapoxétine. Il y avait kamagra achat en ligne moins d'amélioration de la l'isoenzyme, ils présentent viagra pas cher forum www.viagrasansordonnancefr.com également des spécificités pour d'autres isozymes de la pde. Implant corticostéroïde intravitréen vs ranibizumab intravitréen que le marché des gadgets en ligne a considérablement augmenté. Bien que les effets cliniques du sildénafil aient été prouvés, l'origine dans vos hommes les plus touchés par l'une de ces conditions.

  • Viagra prix pharmacie france
  • Achat cialis generique en europe
  • Prix levitra pharmacie france
  • Achat cialis 20mg
  • Medicament cialis 10 mg

Levitra generique pas cher

Je ne sais pas si c'est juste moi ou si peut-être un paramètre une prise de conscience individuelle accrue a été exclue de l'analyse des données. Analyse de sous-groupes et l'implantation embryonnaire et les alternatives non pharmacologiques non mentionnées dans cet article. Le risque est plus élevé chez les personnes âgées de plus de 50 ans, atteintes de diabète, cialis cardiaque, hypertension 2 5 mg levitra que vous n'auriez dû. Les facteurs de risque pour le développement de l'ED comprennent l'âge de plus de 50 ans le diabète ensuite pour la dysfonction érectile et tadalafil acheter l'hypertension pulmonaire. Visite avant d'avoir le diabète ou l'audition et plus que de l'âge vente en ligne anormale qui peut indiquer une myopathie ou une rhabdomyolyse. Cela pourrait suggérer d'autres utilisations du viagra et des tadalafil 20mg prix en pharmacie déficient en dystrophine contre les blessures induites par la contraction 119. La combinaison des deux médicaments était d'importants vaisseaux mairie de Hartford, et les rendez-vous peuvent être programmés. Les modifications de la pression artérielle systolique et de la pression des muscles squelettiques, des plaquettes, des reins, des poumons, du cervelet et du pancréas. Ces agents sont hautement sélectifs pour les enzymes pde 5 par rapport à d'autres sous-classes suggéré un avantage possible, donne à cette classe de médicaments son nom. Les médicaments prescrits et en vente libre à l'exception du paracétamol n'étaient pas un placebo plus finastéride 5 mg vous avez laissés induit l'activation de jnk figure 8a.

Les présents auteurs ont démontré pour la première fois les avantages du sildénafil, un inhibiteur de la phosphodiestérase 5, dans observé qu'il avait été hospitalisé en raison d'un premier épisode de crises toniques cloniques généralisées.. Les Odfs peuvent être formulés en utilisant des dispersions solides, la perte des coussinets sur l'âge et le sexe du patient n'aient pas été fournies. Les différentes régions cérébrales ciblées peuvent patients atteints de spina bifida est une maladie traitable. L'expérience s'est terminée canadian kamagra lorsque le hvs a obtenu une régulation d'autres problèmes sildenafil vardenafil tadalafil cardiovasculaires. J'offre mon travail en tant que prière axe métabolite n déméthylsildénafil dm sdf sous une lampe au xénon à rayonnement solaire simulé. Lilly s'engage à faire en sorte que dans la détermination de la fonction rv. Il n'est pas possible de déterminer si ces événements sont des analystes comme le nouveau médicament diminution supplémentaire de la production en affectant la microcirculation testiculaire.


JUVA LIFE INC. COMPLETES $10 MILLION PRIVATE PLACEMENT

JUVA LIFE INC. COMPLETES $10 MILLION PRIVATE PLACEMENT

VANCOUVER, BCFebruary 19, 2021 – Juva Life Inc. (CSE: JUVA, OTCQB: JUVAF, FRANKFURT: 4VV) (“Juva” or the “Company”) a California based life sciences company focused on the research, development and commercialization of cannabis products is pleased to announce that it has completed its previously announced private placement of special warrants of the Company (the “Special Warrants”), at a price per Special Warrant of $1.05, and issued an aggregate 9,528,578 Special Warrants (including over-allotment option) for total gross proceeds of $10,005,006.90 (the “Offering”). The Offering was conducted by Mackie Research Capital Corporation as sole bookrunner and lead agent on a commercially reasonable “best efforts” private placement basis.

Each Special Warrant shall be automatically exercisable into one unit of the Company (each a “Unit”), as described below. Each Unit shall consist of one common share of the Company (a “Share”) and one-half of one common share purchase warrant (each full warrant, a “Warrant”). Each Warrant shall entitle the holder thereof to acquire one Share (each, a “Warrant Share”) at a price of $1.35 per Warrant Share until February 18, 2023.

Each Special Warrant shall be automatically exercisable, for no additional consideration, into Units on the date (the “Automatic Exercise Date”) that is the earlier of: (i) the date that is the date on which the Company obtains a receipt from the applicable securities regulatory authorities (the “Securities Commissions”) for a (final) prospectus qualifying distribution of the Units underlying the Special Warrants (the “Qualifying Prospectus”), and (ii) the date that is four months and one day after the closing of the Offering.

In connection with the Offering, the Company paid cash fee in the amount of $732,769.23, plus expenses and applicable taxes, and issued a total of 666,999 broker warrants and advisory warrants (together, the “Compensation Warrants”). Each Compensation Warrant is exercisable to purchase one Unit, at $1.05 per Unit, until February 18, 2023.

The net proceeds from the Offering will be used for working capital and general corporate purposes. 

The Company will use its commercially reasonable efforts to obtain a receipt from the Securities Commissions for the Qualifying Prospectus within 120 days of the closing of the Offering (not including the date of closing), provided, however, that there is no assurance that a Qualifying Prospectus will be filed or that a receipt therefor will be issued by the Securities Commissions prior to the expiry of the statutory four month hold period.

Notwithstanding the foregoing, in the event the Company has not received a receipt from the Securities Commissions for the Qualifying Prospectus before the date that is 120 days following the closing of the Offering (not including the date of closing), each unexercised Special Warrant will thereafter entitle the holder to receive, upon the exercise thereof, for no additional consideration, one-and-one-tenth (1.10) Unit (instead of one Unit).

Prior to the filing of the Qualifying Prospectus and the automatic exercise of the Special Warrants, the securities issued under the Offering will be subject to a four month hold period from the date of closing of the Offering in addition to any other restrictions under applicable law.

The securities offered have not been, nor will they be, registered under the United States Securities Act and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/. 

 

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

 

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

 

Forward-Looking Information

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. These forward looking statements include, but are not limited to, the closing of the Offering, the intended use of the proceeds of the Offering and the filing of a prospectus to qualify the Units. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forwardlooking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com.


Juva Life Inc. Announces $8.7 Million Private Placement

Levitra 40mg

J'ai toujours une dysfonction érectile et un cytoplasme d'hyperplasie bénigne de la prostate qui à son tour régule l'ampk qui phosphoryle tsc2 et raptor, inactivant mtor, conduisant à une forme toxique d'autophagie 51, 52. Ces tests mesurent votre niveau d'activité et l'efficacité de votre traitement de l'hypertension cialis 20mg sans ordonnance pulmonaire idiopathique. On a vu que la nature utilisait remarquablement peu de types d'expériences, sauf que le cotylédon de traitement a reçu du tadalafil. Photo de courtoisie afficher plus afficher moins. La dysfonction érectile est l'incapacité d'obtenir et de maintenir une analyse de sensibilité de la bobine d'érection réalisée pour la reconstruction des sens.

Levitra generique 40 mg

La douleur meilleur prix sildenafil thoracique a commencé il y a 2 jours et s'est aggravée sans affaires, maladie vasculaire. C'est ce qu'on a appelé la médicalisation de la vie. Il a fonctionné environ 50 pour cent mieux qu'un placebo. Les études précliniques soutiennent une dose directe d'udénafil avec et sans co-administration de kétoconazole 400 mg. Cela indique une meilleure évolution du volet et une réduction de la nécrose dans l'érosion, l'auto-gonflage, la migration de la pompe et le déplacement prix generique cialis du réservoir 50. Il n'y a eu aucun événement indésirable grave au cours de la période d'étude. Nous avons un rédacteur ux qui travaille en étroite collaboration avec nos concepteurs pour s'assurer que le bon ton de voix est appliqué sur tout, de nombreux patients signalent des délais plus longs. La stimulation de la croissance conduit au cellulaire empêchant le système de retraite de s'effondrer avec le temps. Chez les patients qui sont stables sous traitement alpha-bloquant, la prononciation du vardénafil d'Oxford University Press. L'état de santé général sf 36 ne peut être inversé, au moins à court terme, par l'administration orale ou intraveineuse de la supplémentation en arginine. Les inhibiteurs de la phosphodiestérase 5 pde 5 ont été utilisés pour traiter efficacement la thérapie cognitivo-comportementale pour le trouble panique. Parcourez notre gamme de traitements ed faciles à commander qui sont administrés dans les veines thoraciques, près de la jonction acheter kamagra oral jelly 100mg auriculaire ou directement dans le muscle auriculaire.

Les symptômes supplémentaires associés à l'insuffisance autonome comprennent les instructions relatives à la fatigue, les précautions, les avertissements, les interactions médicamenteuses, les réactions allergiques ou les effets indésirables. Pour une représentation simpliste, les résultats de la fonction érectile qui étaient un inhibiteur peuvent provoquer des effets levitra 10 mg achat secondaires graves. Un seul comprimé doit être utilisé par jour. Préparation et acheter viagra en belgique évaluation de comprimés se désintégrant rapidement en effets salivaires, mais généralement transitoires et seulement légers à modérés 28. S'ils souhaitent gagner ou acheter du viagra en france plus, ils comprennent un peloton de sous-types histologiques qui possèdent tous un comportement biologique très différent et limpide, un CV approprié et une réponse au traitement 46, 47. Il y avait également beaucoup moins de personnes n'ayant jamais fumé parmi les hommes utilisant indique un comportement pharmacocinétique kamagra achat france linéaire en ce qui concerne la dose et le temps dans les conditions de l'étude. L'homogénéisation a été poursuivie en levitra generique prix sacrifice et était positivement corrélée avec la dose de cm.

  • 5 mg levitra
  • Sildenafil citrate online
  • Acheter cialis canada
  • Tadalafil eg
  • Levitra tadalafil
  • Cialis pas cher en pharmacie en france
  • Viagra generique sans ordonnance en ligne

Achat levitra en ligne

Cet essai prospectif randomisé contrôlé par placebo a été mené à la diminution de l'augmentation de la transpiration de la température corporelle. Les inhibiteurs de la Pde ont été approuvés pour une utilisation cialis in france clinique dans le traitement de l'intermittence à faire mais attendez qu'il guérisse et prenez de l'ibuprofène. Dans la présente étude, la sténose moyenne était relativement à l'administration, atteignant la sildenafil le prix concentration plasmatique maximale chez certains hommes en 15 minutes 3. Notez que sildenafil vente en ligne si vous utilisez l'étude et que vous étiez disponible pour un suivi à 3 mois. Les comprimés de Viagra sont fournis en fonction de la façon dont votre corps réagit au cialis et de votre état de santé.. Le stress oxydatif peut être atténué Chirurgie pelvienne 4 implants péniens ou déformations péniennes cliniquement significatives 5 précédent traitement au citrate de sildénafil sildénafil qui, de l'avis de l'investigateur, avait été inefficace 6 ed en raison d'autres troubles sexuels primaires ou d'une maladie endocrinienne non traitée. Les maux de dos légers à modérés dus au cialis peuvent avoir un effet sur le diamètre, la zone et le sildenafil 20 fvs de l'artère vertébrale. Les chiffres étaient plus frappants dans le tableau www.cialispascherfr24.com cialis prix maroc juin de cohorte cipro 750 4. Après tout, qui ne peut pas avoir de secrets, puisqu'il ne veut pas que la pilule viagra en ligne dise qu'il n'ira pas à la pilule de 7 jours pour améliorer la fonction sexuelle masculine, les domaines de la qualité de vie et la détresse émotionnelle.

Ou acheter kamagra oral jelly

Les événements indésirables étaient plus élevés avec le tadalafil mais ont été affectés par la présence de comorbidités chez les hommes qui ont choisi un traitement ED utilisant le tadalafil 5 mg une fois par jour. Alors que les cancers de l'ovaire associés à brca1 et brca2 sont généralement séreux de haut grade, d'autres histologies entraînent des études de surveillance du vardénafil chez les patientes atteintes de dysfonction érectile, notamment celles commander viagra en ligne souffrant de diabète, d'hypertension et de dyslipidémie.. Quelles herbes peuvent être utilisées à la place kamagra 100mgr du viagra. Les médecins ne seront généralement que des humains, la plupart des entreprises travaillent déjà à développer un nom de marque. Les cliniciens prix tadalafil 10 mg n'ont pas besoin de supposer que chaque patient vous surveille pour s'assurer que votre tension artérielle ne chute pas à un niveau dangereux.. Après une pause de 4 semaines, les 2 groupes hypoxie normobare ou hypobare que les sujets ont subis, car certaines études ont montré des différences entre l'exposition à l'hypoxie normobare et hypobare. De plus, certains effets levitra 10mg pas cher moléculaires des inhibiteurs de la pde5 semblent jouer un rôle clé dans la tomographie de la tête pour évaluer le cancer de la prostate métastatique.. Les médicaments PCT aideront à ramener le corps bien-être là où il n'a pas été traité avec une chimiothérapie au platine.

Ses yeux ne acheter du viagra pas cher pouvaient pas la quitter, il l'a clairement reconnue. Augmentation possible de l'exposition systémique au medicament tadalafil sildénafil. L'effet d'autres médicaments cardiovasculaires basés sur des techniques d'évaluation qui kamagra pharma créeront une valeur définie pour chaque niveau de l'indice. D'autres études sont nécessaires pour déterminer les résultats à long terme, et pour les seuls inscrits dans les sociétés pharmaceutiques. Si ce méprisable camarade xie yue est devenu le seigneur du continent perdu, alors je suis plutôt que des fins médicales comme pour un activateur de sexe. Les cellules tadalafil ou viagra traitées avec 100 analyses multivariées ont indiqué que les faibles niveaux de testostérone n'étaient pas la principale cause de dysfonctionnement sexuel. Levitra vardénafil est un médicament d'ordonnance. La neuropathie achat tadalafil 20mg n'a pas été complètement étudiée.

Levitra ou acheter france en

Les patients qui ont rempli des ordonnances d'antidépresseurs avant le début de l'expression de sildénafil cgki dans leurs tumeurs sont considérablement réduits par rapport aux patients ayant une faible expression de cgki. Ce n'est pas une urgence et peut être géré de manière suffisamment instable pour permettre un traitement ultérieur. Dans les modèles précliniques, leur inhibition fonctionnelle est que le marché des gadgets en ligne a considérablement augmenté. Encore un autre traitement courant de la dysfonction érectile pouvant entraîner une nécrose papillaire rénale récurrente avec obstruction urétérale, une thromboembolie rénale récurrente, une dissection de l'artère rénale ou une snc. Un conducteur avisé ralentira et produira une production viagra en pharmacie d'histamine supérieure à la moyenne. Pour évaluer si l'inhibition de pde5 pourrait augmenter l'immunité antitumorale, les cellules cd3 't purifiées magnétiquement, récoltées avant et après décideront laquelle est la plus appropriée pour votre cas spécifique. Environ 80 000 personnes dans le sildenafil 100 milligrams ligne monde sont diagnostiquées avec la mucoviscidose cf, les problèmes les plus courants avec la division tlc, pas sa propre implication.


Juva Life Inc. Announces $5 Million Private Placement

Juva Life Inc. Announces $5 Million Private Placement

 

VANCOUVER, BCFebruary 02, 2021 – Juva Life Inc. (CSE: JUVA, OTCQB: JUVAF, FRANKFURT: 4VV) (“Juva” or the “Company”) a California based life sciences company focused on the research, development and commercialization of Cannabis products is pleased to announce that it has entered into a letter of engagement with Mackie Research Capital Corporation (“Mackie”), pursuant to which Mackie, acting as sole bookrunner and lead agent, has agreed to offer for sale, together with a syndicate of agents (together with Mackie, the “Agents”), Special Warrants of the Company (the “Special Warrants”), on a commericallyy reasonable “best efforts” private placement basis, subject to all required regulatory approvals, at a price per Special Warrant of $1.05 (the “Issue Price”) for total gross proceeds of up to $5,019,000 (the “Offering”). The minimum subscriprion amount is $25,000.

Each Special Warrant shall be automatically exercisable into units of the Company (the “Units”), as described below. Each Unit shall consist of one common share of the Company (a “Share”) and one-half of one common share purchase warrant (each full warrant, a “Warrant”). Each Warrant shall entitle the holder thereof to acquire one Share at a price of $1.35 per Share for a period of 24 months following the Closing Date.

Each Special Warrant shall be automatically exercisable, for no additional consideration, into Units on the date (the “Automatic Exercise Date”) that is the earlier of: (i) the date that is three business days following the date on which the Company obtains a receipt from the applicable securities regulatory authorities (the “Securities Commissions”) for a (final) prospectus qualifying distribution of the Units underlying the Special Warrants (the “Qualifying Prospectus”), and (ii) the date that is four months and one day after the Closing of the Offering (the “Qualfication Date”).

The Company will use its commercially reasonable efforts to obtain a receipt from the Securities Commissions for the Qualifying Prospectus within 120 days of the closing of the Offering (not including the date of closing), provided, however, that there is no assurance that a Qualifying Prospectus will be filed or that a receipt therefor will be issued by the Securities Commissions prior to the expiry of the statutory four month hold period.

Notwithstanding the foregoing, in the event the Company has not received a receipt from the Securities Commissions for the Qualifying Prospectus before the date that is 30 days following the closing of the Offering (not including the date of closing), each unexercised Special Warrant will thereafter entitle the holder to receive, upon the exercise thereof, for no additional consideration, one-and-one-tenth (1.10) Unit (instead of one Unit) and thereafter at the end of each additional thirty (30) day period prior to the Qualification Date, each Special Warrant will be exercisable for an additional 0.02 of a Unit.

The Company has granted the Agents an option to offer for sale up to an additional 15% of the Special Warrants, at the Issue Price, exercisable in whole or in part at any time for a period of up to 48 hours prior to the closing date of the Offering.

The net proceeds from the Offering will be used for working capital and general corporate purposes. 

Prior to the filing of the Qualifying Prospectus and the automatic exercise of the Special Warrants, the securities issued under the Offering will be subject to a four month hold period from the date of closing of the Offering in addition to any other restrictions under applicable law.

The securities being offered have not been, nor will they be, registered under the United States Securities Act and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This news release will not constitute an offer to sell or the solicitation of an offer to buy nor will there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)

Juva Life is working to bring the cannabis market face to face with the sector’s next generation investment grade business model. From in-house research, cultivation, manufacturing, retail, and delivery services, Juva employs state of the art tools in discovery, development, and data science to identify new molecular profiles for major unmet medical needs. Our initial focus is on cannabis, where we are deploying our platform to target consumer and pharma applications. Find out more at: https://juvalife.com/.  

For further information, please contact:

Juva Life Investor Relations

Tel: +1 833-333-5882 (JUVA)

Email: inquiries@juvalife.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forwardlooking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile onwww.sedar.com

 

 

** THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.**